Genzyme's Clolar fails to gain support of FDA panel

09/2/2009 | Reuters

Genzyme did not get support from an FDA advisory panel to market pediatric leukemia drug Clolar to adults with acute myeloid leukemia. In a 9-3 vote, the panel advised the company to conduct a randomized trial of Clolar to provide "an evidence-based justification" that the product is more effective than other treatments.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY